Skip to main content
Tech.euFundingExplorerBeta

CoV Biotechnology

Exited

CoV Biotechnology is an early-stage Singapore-based biotechnology company focusing on inducing broad, pan-sarbecovirus immune responses to address the evolving and mutating nature of the coronavirus.

Total raised
€0
€0
Funding rounds
0
Investors
0
distinct backers
Active since

Funding rounds

0 rounds
No funding rounds recorded.

Exit

Type
acquisition
Date
Jan 2025
Value
Acquiror
Leyden Labs (Netherlands)

Related news

Similar companies

same sector or country